Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HMPL-760

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Hutchmed

Phase 3 Most advanced trial
HCM Developer
2 Registered trials

What is HMPL-760?

HMPL-760 is a reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), including the wild-type enzyme and the C481S mutant form. By blocking BTK it inhibits B-cell antigen receptor signaling and the growth of malignant B cells. It is being studied in relapsed or refractory diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor signaling, BTK-mediated survival signaling
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07409428 Phase 3 Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting HCM
NCT06601504 Phase 2 Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Other drugs acting on BTK

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind HMPL-760

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.